ClinicalTrials.gg
RecruitingNCT06851377OGMUpdated Feb 28, 2025

Expanding NGS Data with Optical Genome Mapping (OGM)

An interventional study of Optical Genome Mapping (OGM) and Whole Genome Sequencing (WGS) and Trascriptome analysis in Neurodevelopmental Disorder (Diagnosis), sponsored by IRCCS Eugenio Medea. Recruiting at 1 site in Italy. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by IRCCS Eugenio Medea · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled May 2024, registered Feb 2025).
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Neurodevelopmental Disorders with a site in Italy — 18 open to participants now, 24 under way, 6 of them phase 3. Neurodevelopmental Disorders · Italy.

Planned enrollment
16th of 25
60 · median 80
Started
2024
with 9 others
No phase
18 of 35
9 open now
Primary completion
2026-12
later than 13 of 23 live
Registered
24th of 35
by date
Lead sponsor
7 of 35
IRCCS Eugenio Medea

Among the 35 studies in Neurodevelopmental Disorders with a site in Italy, this one is the 16th largest by planned enrollment of the 25 interventional ones that give a count, is one of 10 that started in 2024, is one of 18 with no phase, reaches primary completion later than 13 of the 23 other live ones, and was the 24th registered.

Neurodevelopmental Disorders

355 studies on the registry are indexed under Neurodevelopmental Disorders; 144 are open to participants now.

Browse Neurodevelopmental Disorders studies →

Open to participants now

18 of the 35 studies in Neurodevelopmental Disorders with a site in Italy are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Neurodevelopmental Disorders with a site in Italy, or all of them as a file.
02

Study summary

Over 50% of pediatric neurological and neurodevelopmental disorders lack a molecular diagnosis after standard DNA sequencing and molecular karyotyping. This is due to technical limitations, incomplete variant interpretation, and inadequate genotype-phenotype correlations. New sequencing technologies are crucial for clinical decision-making, offering complete profiles of variants in a patient's DNA to personalize treatment. Optical Genome Mapping (OGM) can detect nearly all structural variants in one experiment. This project aims to use OGM alongside NGS to improve diagnostic yield in 60 children with severe disorders who tested negative for NGS/CMA.

03

Conditions studied

  • Neurodevelopmental Disorder (Diagnosis)

Keywords

  • Optical Genome Mapping, neurodevelopmental disorders, genome sequencing
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • individuals without a molecular diagnosis (negative to ES/CMA analyses);
  • individuals with genetic diagnoses that explain only one component of their primary phenotype;
  • individuals carrying one or more variants of uncertain clinical significance
  • individuals with a phenotype highly reminiscent of clinically and molecularly well-defined syndromes (i.e., Marfan Syndrome) but negative to routine molecular analysis.

Exclusion criteria

Exclusion Criteria:

  • individuals who have not undergone initial diagnostic genetic tests (ES/CMA)
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Expanding NGS data with Optical Genome Mapping (OGM)

    OGM will be used alongside WGS to improve diagnostics in 60 children with severe NDDs lacking a molecular diagnosis after initial CMA and exome analyses.

    Genetic: Optical Genome Mapping (OGM) and Whole Genome Sequencing (WGS) · Other: Trascriptome analysis

Interventions

  • GeneticOptical Genome Mapping (OGM) and Whole Genome Sequencing (WGS)

    After identifying causal SVs via OGM, WGS will determine rearrangement breakpoints and examine nearby genes within 100 kb that may have altered expression due to positional effects.

  • OtherTrascriptome analysis

    Following genomic characterization results, transcriptome analysis will be performed on patient-derived lymphoblastoid B-cell lines or fibroblasts to investigate the molecular implications of candidate SVs found in the OGM analysis and identify potential transcriptome abnormalities, such as splicing variants, in patients with atypical clinical features.

06

What researchers measure

Primary outcomes

  1. Genotype-phenotype correlation

    Number of pathogenic structural variants found by OGM explaining the phenotype

    Time frame: once at recruitment

07

Study locations

1 of 1 sites recruiting
  • Cytogenetic Unit of Medical Genetic Laboratory
    Bosisio Parini, Lecco 23842, Italy
    Recruiting
    • Maria C Bonaglia, Master Degree · Contact+39 031877913
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 142 non-industry interventional studies with no phase under Neurodevelopmental Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 31 months is close to that.

Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 15 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Feb 28, 2025
StartActual
May 23, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06851377
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
May 23, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 28, 2025

Study contacts

Maria Clara Bonaglia PhD
Contact
mariaclara.bonaglia@lanostrafamiglia.it
+39 031 877913

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion